NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
The persistent challenge of opioid addiction, involving substances such as heroin, fentanyl, and oxycodone, remains a significant public health concern both in the United States and globally. A key obstacle in addressing this addiction crisis is the management of withdrawal symptoms. The symptoms include intensified pain, nausea, excessive sweating, and mental health issues like depression and anxiety. Often resembling a severe flu, these symptoms can be life-threatening, and the fear of experiencing these symptoms contributes to opioid users’ reluctance to stop taking their drug.
The interest of NIDA in PN6047, prompted by the drug's very positive effects on neuropathic pain, reflects the ongoing efforts of NIDA to find effective treatments for opioid withdrawal.
Comprehensive data from preclinical studies suggest that PN6047 has no abuse potential. This is further supported by Phase I clinical data, where no side effects indicating abuse potential have been observed. Ongoing studies in the NIDA project have also demonstrated the candidate’s effectiveness in pain relief during intensified pain due to opioid withdrawal and its potential to alleviate symptoms of depression and anxiety.
Phase I study data of PN6047 have shown promising results regarding safety and tolerability, paving the way for additional studies of PN6047 in opioid withdrawal syndrome, with a potential for support from NIDA.
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
The persistent challenge of opioid addiction, involving substances such as heroin, fentanyl, and oxycodone, remains a significant public health concern both in the United States and globally. A key obstacle in addressing this addiction crisis is the management of withdrawal symptoms. The symptoms include intensified pain, nausea, excessive sweating, and mental health issues like depression and anxiety. Often resembling a severe flu, these symptoms can be life-threatening, and the fear of experiencing these symptoms contributes to opioid users’ reluctance to stop taking their drug.
The interest of NIDA in PN6047, prompted by the drug's very positive effects on neuropathic pain, reflects the ongoing efforts of NIDA to find effective treatments for opioid withdrawal.
Comprehensive data from preclinical studies suggest that PN6047 has no abuse potential. This is further supported by Phase I clinical data, where no side effects indicating abuse potential have been observed. Ongoing studies in the NIDA project have also demonstrated the candidate’s effectiveness in pain relief during intensified pain due to opioid withdrawal and its potential to alleviate symptoms of depression and anxiety.
Phase I study data of PN6047 have shown promising results regarding safety and tolerability, paving the way for additional studies of PN6047 in opioid withdrawal syndrome, with a potential for support from NIDA.
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more